StockData

IGC Pharma vs MediciNova

IGC and MNOV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IGC and MNOV compare

MediciNova is the larger company, worth 3.4 times as much as IGC Pharma ($69.4M against $20.6M).

IGC Pharma keeps more of each dollar of sales as profit, with a net margin of −702% compared with −1168% at MediciNova.

MediciNova scores higher on the StockData Score (7 against 2 for IGC Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIGCMNOV
Size and price
Market cap$20.6M$69.4M
Share price$0.199$1.41
Change, 1 year−48.2%0.00%
Change, 5 years−86.1%−56.1%
Beta (5Y)0.610.39
Employees676
StockData Score
Total score27 (better)
Valuation score01 (better)
Growth score00
Performance score11
Health score15 (better)
Dividend score00
Valuation
P/S18.3× (better)75.4×
P/B3.2×1.9× (better)
FCF yield–−13.1%
Fair value$0.165–
Margin of safety−20.5%–
Growth
Revenue growth (TTM)−15.4%–
Profitability
Gross margin21.9%–
Operating margin−987% (better)−1287%
Net margin−702% (better)−1168%
FCF margin–−991%
Return on equity−113%−25.6% (better)
Return on invested capital−136%−76.6% (better)
Financial health
Debt / equity0.02 (better)0.00
Current ratio0.428.75 (better)
Altman Z-score−19.08−2.46 (better)
Piotroski F-score–2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions5.1%10.5%
Held by insiders13.2%12.8%
Insider net buying, 12 months–−$1.7M
Short interest, % of float0.44%0.66%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.